LMS-Dr. Can Bioscience Inc
LMS-Dr. Can Bioscience Inc serves as a specialised Contract Research Organisation (CRO) that supports the life sciences industry through a comprehensive suite of animal experimentation and laboratory services. Our robust infrastructure features five core technology platforms, including genetically modified disease models, histopathology, and advanced omics technologies. We provide end-to-end research support, ranging from initial protocol design and model development to complex bioinformatics and data analysis. By utilising cutting-edge tools like brain-computer interfaces and 3D electron microscopy, we aim to accelerate global drug discovery and improve human health outcomes. Our service model emphasises a collaborative partnership approach, offering both standardised assays and customised research solutions for pharmaceutical firms and academic institutions.
If an overseas drug manufacturer is seeking to seamlessly outsource the R&D operations, LMS-Dr Can Bioscience serves as a comprehensive, one-stop Contract Research Organisation (CRO) capable of handling your intricate preclinical needs:
What?
We offer a highly structured Research Service Matrix that spans from standard routine animal models, histopathology, and biochemical assays to highly complex custom research, such as gene-modified models and multi-omics integration. Crucially, we provide robust drug evaluation services, including vital pharmacokinetic/pharmacodynamic (PK/PD) assessments and toxicology evaluations. By offering specialised disease models tailored for critical therapeutic areas like cardiovascular diseases, tumours, and neurological disorders, LMS-Dr.Can position itself as a critical hub in the life science industry chain, designed to accelerate your global drug discovery efforts. To successfully execute the outsourced projects, LMS-Dr.Can leverage a structured, end-to-end collaboration model powered by five core technology platforms: Disease Animal Models, Histopathology, Cell Biology, Molecular Biology, and Omics Technologies.
Stay in touch
How?
We manage the process through a five-step methodology—Consultation, Agreement, Execution, Delivery, and Partnership—ensuring we receive personalised project management and periodic progress reports at every stage. During execution, they employ multidimensional data collection techniques, ranging from advanced behavioural testing and micro-CT imaging to comprehensive multi-omics integration that informs molecular docking. This end-to-end support system ensures our drug candidates are evaluated through rigorous quality control and highly traceable data, culminating in detailed analysis and even assistance with manuscript publication.
Research Outlook?
Outsourcing to LSM-Dr.Can represents more than a transactional vendor relationship; it is a "Sustainable Partnership" designed for deep collaboration and ongoing research support. The strategic focus on "Frontier Exploration" means our R&D pipeline will continually benefit from cutting-edge technologies, including in vivo brain-computer interfaces (BCIs) for neurological studies, 3D electron microscopy, and advanced proteomics. By functioning as a technology-driven partner committed to continuous innovation, we guarantee that our future drug development efforts will remain at the forefront of life science, ultimately fulfilling our shared mission of providing safer, more effective solutions to safeguard human health globally.
